Fake FDA Officials Capitalize on India Compliance Issues

Indian Regulators have warned both Indian and foreign pharmaceutical companies to beware of a scam involving people posing as U.S. FDA officials, demanding cash payments for approvals.

A western Indian homoeopathic company’s manufacturing facility was visited last month by an FDA "inspector" who informed the company that an FDA approval was in progress, but required a $418 cash payment. The company, later identified by in-pharmatechnologist as local company, Muktesh Healthcare, alerted the Gujarat Food and Drugs Control Administration of the possible scam.

The scam comes at a vulnerable time for India drugmakers, as recent regulatory action on behalf of the U.S. FDA has banned several Indian drugmakers from exporting drugs to the U.S. and a global spotlight has be cast on India compliance issues.

Read the International Business Times story

More News:

  • WuXi Single-Use Biotech Facility Gets ISPE FOY Nod

    WuXi PharmaTech recently announced it received an honorable mention from the ISPE 2014 Facility of the Year Awards committee for the company's recently completed cGMP cell-culture-based biologics production facility in Wuxi, China.

  • Fake FDA Officials Capitalize on India Compliance Issues

    Indian Regulators have warned both Indian and foreign pharmaceutical companies to beware of a scam involving people posing as U.S. FDA officials, demanding cash payments for approvals.

All news »

What are your comments?

You cannot post comments until you have logged in. Login Here.

Comments

No one has commented on this page yet.

RSS feed for comments on this page | RSS feed for all comments